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ABSTRACT The interactions of agonists and antagonists with
j3-adrenergic receptors on intact 1321N1 human astrocytoma and
C62B rat glioma cells were studied by using the radioligand (-)-
['25I]iodopindolol. Competition binding assays were performed at
37°C under equilibrium conditions and in short-time nonequilib-
rium assays that approximated initial velocity conditions for bind-
ing of the radioligand. The theoretical basis and experimental val-
idation of the initial velocity approach for determining binding
affinities of rapidly equilibrating ligands are presented. For the
agonists isoproterenol and epinephrine, high binding affinities that
approximated their apparent affinities for binding in membranes
and for increase of cyclic AMP concentrations in intact cells could
be demonstrated only in short-time assays; in contrast, much lower
affinities were observed with equilibrium (60-min) assays as re-
ported previously for various cell lines. High-affinity binding of
isoproterenol to 1321N1 cells also was observed in equilibrium (6-
hr) binding assays carried out on ice. These results indicate that
in the native state the intact cell fl-adrenergic receptor has a high
binding affinity for agonists and suggest that incubation at 37°C
in the presence of an agonist converts the receptors to a form with
low affinity for agonists.
The apparent binding affinity of ,B-adrenergic receptor ago-
nists, as measured by their capacity to inhibit radiolabeled an-
tagonist binding to intact cells, has been shown to be markedly
lower than the apparent affinity of these agonists in stimulation
of cyclic AMP accumulation and in binding to receptors in
membrane preparations (1-3). In contrast, the binding affini-
ties for antagonists are in good agreement both with their ap-
parent affinities in inhibition of agonist-stimulated cyclic AMP
accumulation in intact cells and with their affinities in binding
to receptors in membrane preparations. In assays of membrane
preparations, receptor binding affinities for both agonists and
antagonists are in good agreement with their apparent affinities
in stimulation or inhibition of adenylate cyclase.
Although the reason for the low affinity of agonists observed
in intact cell binding assays is unknown, it is well recognized
that exposure of cells to agonists can lead to rapid changes in
both the physical and pharmacological properties of ,3adren-
ergic receptors (4-9). Thus, agonist-induced conversion of /3-
adrenergic receptors from a native form with high affinity for
agonists to a low-affinity form during the time course of an
equilibrium competition binding assay could account for these
results. Two previous studies have considered this possibility.
Terasaki and Brooker (1) were unable to detect high-affinity
binding of agonists to C62B rat glioma cells at assay times as
short as 2.5 min, and they suggested that the low binding af-
finity observed was due to the existence of "spare receptors."
They concluded that binding to as little as one receptor per C62B
cell was sufficient to fully activate adenylate cyclase. In con-
trast, Pittman and Molinoff (2), using a different cell line (L6
rat muscle cells), demonstrated that isoproterenol inhibited ra-
diolabeled antagonist binding at short assay times (<2 min) more
effectively than at longer incubation times and presented evi-
dence suggesting that the low binding affinity observed in
equilibrium assays was due to a rapid change in receptor af-
finity occurring during incubation of these cells with agonists.
To test the possibility that rapid decreases in binding affinity
for agonists might be occurring during the time course of equi-
librium binding assays, an approach was developed for the de-
termination of equilibrium dissociation constants (Kd) for com-
peting ligands by using short-time competition binding assays
under nonequilibrium conditions of binding of the radioligand.
By using this method, high-affinity binding of agonists to A-ad-
renergic receptors of intact 1321N1 human astrocytoma cells
and C62B rat glioma cells can be readily demonstrated. High-
affinity binding of agonists also is expressed even after pro-
longed incubation in the presence of agonist to achieve equi-
librium binding if the assays are performed at reduced tem-
perature.
MATERIALS AND METHODS
Materials. (-)-Isoproterenol bitartrate and (±)-propranolol
hydrochloride were obtained from Sigma. The following drugs
were generous gifts: (-)-pindolol from Sandoz Pharmaceutical,
(-)-epinephrine bitartrate from Sterling-Winthrop Research
Institute (Rensselaer, NY), (-)-propranolol hydrochloride from
Ayerst Laboratories (New York), and (+)-metoprolol from P. B.
Molinoff and B. B. Wolfe. C62B rat glioma cells were gener-
ously provided by Gary Brooker and Ken Barovsky. (-)H[125I]-
Iodopindolol ('25I-Pin) was prepared by a modification (10) of
the method of Barovsky and Brooker (11).
Cell Culture. Human astrocytoma cells (1321N1) were main-
tained in Dulbecco's modification of Eagle's medium supple-
mented with 5% fetal calf serum. Rat glioma cells (C62B, pas-
sage 30-40) were maintained in Eagle's medium supplemented
with pyruvic acid (1 mM), asparagine (0.2 mM), serine (0.2 mM),
and 5% fetal calf serum. Growth of cells was carried out under
an atmosphere of 92% air and 8% CO2 at 37°C in a humidified
incubator. Cells taken from confluent flasks were seeded in 35-
mm culture dishes (Falcon) at a density of 80,000 cells per dish
and used on the fourth day after subculture.
Binding of '25I-Pin to Intact Cells. The binding assay used
for 1321N1 cells was a modification of the procedure of Barov-
sky and Brooker (11). Cell sheets were rinsed with 2 ml of serum-
free Eagle's minimal essential medium containing 20 mM Hepes
(pH 7.4). One milliliter of Eagle's/Hepes medium containing
'25I-Pin, 1 mM sodium ascorbate, and various concentrations
Abbreviation: '25I-Pin, (-)-['25I]iodopindolol.
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of competing ligand was added to each dish and the cells were
incubated at 370C for the time indicated. The binding medium
was then aspirated and the cells were given two 1-min washes
at 370C (1 ml each) with Eagle's/Hepes medium containing (±)-
propranolol (100 MM). Cell-associated radioactivity was deter-
mined after solubilization of the monolayer with 0.2 M NaOH.
Nonspecifically bound radioligand [that bound in the presence
of 1 AM (+)-propranolol] dissociated rapidly at 370C and was
about 5% (equilibrium assays) or 20% (short-time assays) of total
binding after 2 min of washing. Specifically bound radioligand
dissociated slowly, with only about 3% lost during the 2-min
wash. Both kinetic and equilibrium binding studies were con-
sistent with binding of '25I-Pin to a single class of sites with an
equilibrium Kd of approximately 10 pM.
Binding of 125I-Pin to /3-adrenergic receptors on 1321N1 cells
also was measured at a lower temperature (on ice), using the
same wash procedure as for the 370C assays. Equilibrium bind-
ing was obtained after 6 hr, and Scatchard analysis indicated
the same number of receptors labeled on ice as were labeled
at 370C. The Kd value for 125I-Pin binding on ice was approx-
imately 25 pM.
The binding assay used for C62B cells was the same as that
for 1321N1 cells except that the wash procedure was modified
due to the rapid dissociation of specifically bound radioligand
at 37°C. C62B cells were given a 1-min wash followed by a 9-
min wash (1 ml each) on ice. Less than 5% of specific binding
was lost during this wash procedure; nonspecific binding was
approximately 15% (equilibrium assays) or 50% (short-time as-
says) of total binding present after washing. The Kd for 125I-Pin
binding to C62B cells at 37°C was approximately 100 pM.
Data Analysis. Competition curves were analyzed by com-
puterized nonlinear least-squares curve fitting of the raw data
by using the Gauss-Newton method (12). The model used was
that for law of mass action interaction of the competing ligand
with either a single site (n = 1) or two independent sites (n =
2) as follows:
n
Bs = E Bi
i=l
Bn S
i=_ 'i + N
in which S is the concentration of competing ligand, Bs is the
concentration of 1"I-Pin bound at a given value of S, Bi is the
concentration of specific binding sites, Ii is the IC50 for the
competing ligand at each binding site, and N is the concentra-
tion of nonspecific binding sites. It should be noted that this
model is appropriate only if the competing ligand is at equi-
librium with all specific binding sites under the conditions of
the assay.
The single-site and two-site models were compared as de-
scribed (13). Values reported for fractions of high- and low-af-
finity binding sites are reported as arithmetic means; values for
IC50 and Kd are reported as geometric means (14). In all figures,
the data are expressed as a percentage of "2I-Pin specifically
bound in the absence of competing drug. Specific binding in
the absence of competing drugs in 1321N1 cells was approxi-
mately 1,500 cpm in short-time assays and approximately 9,000
or 16,000 cpm in equilibrium assays at 25 pM or 165 pM 125I-
Pin, respectively. The values for C62B cells were approxi-
mately 500 cpm bound per assay at 15 sec and 5,000 cpm bound
per assay at 20 min.
THEORETICAL CONSIDERATIONS
If receptor binding of a competing ligand attains equilibrium
much more rapidly than does that of the radioligand, the con-





in which Rf is free receptor concentration, Rt is total receptor
concentration, [C] is the concentration of free competitor, and
Kdl is the equilibrium dissociation constant for the competing
ligand. If the concentration ofreceptor-bound radioligand ([LR])
is measured at a sufficiently early time such that initial velocity
assumptions apply ([LR] << [LR]eq), then [LR] can be approx-
imated as
[LR] = kont[L]Rf, [3]
in which k0n is the association rate constant for the radioligand,
t is the time of binding, and [L] is the concentration of free




The IC50 is defined as the concentration of competing ligand
required to reduce the amount of radioligand specifically bound
to half the value obtained in the absence of competitor. From
Eq. 4 it can be seen that this will occur when [C] = Kdl. Thus,
the IC50 obtained in binding assays under initial velocity con-
ditions provides an estimate of the equilibrium dissociation
constant for competing ligands that come to equilibrium very
rapidly. As the time at which binding is measured increases, the
competition curves will shift progressively further to the right
until equilibrium is attained, at which time the binding can be
described by the following equation:
[LR] = [5]
1 + (Kd2/[L])(1 + [C]/Kdl)'
in which Kd2 is the equilibrium dissociation constant for the ra-
dioligand. The extent to which the IC50 of the equilibrium curve
is shifted rightward from the true Kd is determined by the con-
centration of radioligand used. The true Kd can be obtained by
dividing the IC50 by the factor (1 + [L]/Kd2) (15).
It should be stressed that this initial velocity method for Kd
determination will be valid only if the competing ligand comes
to equilibrium very rapidly relative to the time over which
binding is measured. If the competitor comes to equilibrium
slowly relative to the time of the assay, the competition curves
obtained will appear to the right of the true Kd due to incom-
plete equilibration of the competitor (16, 17).
RESULTS
Competition Binding Assays with Antagonists. The validity
of the initial velocity method for estimating Kd values was tested
by generating competition binding curves for antagonists with
intact 1321N1 cells under both initial velocity and equilibrium
conditions. The ,B-adrenergic receptor antagonists metoprolol
(Fig. 1) and propranolol (Fig. 2) both inhibited binding of 125I-
Pin with properties consistent with law of mass action inter-
action with a single class of sites. The Kd values calculated from
equilibrium (60-min) assays with metoprolol (Kd = 240 ± 5 nM,
n = 4) and propranolol (Kd = 99 ± 8 pM, n = 3) (all values are
given ± SEM) were both in good agreement with Kd values
obtained in binding assays with membrane preparations and
with the Ki values of the two antagonists for inhibition of iso-
proterenol-stimulated cyclic AMP accumulation in intact cells.
For the rapidly equilibrating antagonist metoprolol, the IC50
(320 ± 13 nM, n = 4) obtained in 1-min assays (Fig. 1) or 15-
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FIG. 1. Competition binding curves for metoprolol with intact
1321N1 cells. 125I-Pin binding to 1321N1 cells was determined in the
presence of the indicated concentrations of (+)-metoprolol at 370C in
either 1-min (D) or 60-min (0, A) assays. The concentration of 1251-Pin
used was either 25 pM (e, o) or 165 pM (A). The points shown are the
averages of two experiments.
see assays (data not shown) was in good agreement with the Kd
calculated from equilibrium assays. The shift observed be-
tween the initial velocity curve and the equilibrium curves ob-
tained at two different radioligand concentrations (Fig. 1) was
thus very near that predicted by the Cheng-Prusoff equation
(15).
Propranolol is a higher affinity ligand than metoprolol and
attains equilibrium only slowly at concentrations near its Kd.
The competition curve obtained in 1-min assays with propran-
olol (Fig. 2, IC50 = 1,600 pM) was shifted to the right relative
not only to the theoretical position (broken line, Kd = 99 pM)
but also to the position of the curve in equilibrium assays. The
curve obtained in 15-sec assays was shifted even further to the
right (data not shown). This is the result expected for a slowly
equilibrating competitor (16, 17). When cells were preincu-
bated for 60 min with various concentrations of propranolol to
allow equilibration with the receptor prior to 1-min competi-
tion assays, an experimental curve indistinguishable from the
theoretical curve (Fig. 2, broken line) was obtained. Thus, the
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FIG. 2. Competition binding curves for propranolol with intact
1321N1 cells. 1321N1 cells were incubated with '25I-Pin (25 pM) and
the indicated concentrations of (-)-propranolol at 3700 for either 1 min
(e) or 60 min (a). The results are the mean ± SEM ofthree experiments.
The broken line is the theoretical binding curve for a competing ligand
with Kd = 99 pM, which is the value obtained for propranolol in equi-
librium assays with intact cells.
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complete equilibration of the competing ligand and is not an
artifact due to nonequilibrium of III-Pin with the receptor.
The results from these studies of antagonist competition for
'2I-Pin binding indicate that short-time assays can provide a
valid measure of the equilibrium dissociation constant for rap-
idly equilibrating competing ligands; for competing ligands that
do not attain equilibrium sufficiently rapidly, short-time assays
will provide an overestimate of the true Kd value.
Competition Binding Assays with Agonists. Agonist com-
petition curves obtained in equilibrium (60-min) binding assays
with 1321N1 cells (Fig. 3) were significantly (P < 0.05) better
fit by a two-component model than by a model for law of mass
action interaction with a single site. For isoproterenol, 13 ± 2%
(n = 4) of 12'I-Pin binding was inhibited with an IC50 of 5.9 ±
1.3 nM and the remaining 86% was inhibited with an IC50 of
41 ± 2 MuM. For epinephrine, 17 ± 4% (n = 3) of "2I-Pin bind-
ing was inhibited with an IC50 of 54 ± 8 nM and the remaining
83% was inhibited with an IC50 of 870 ± 52,uM. Previous stud-
ies (7, 18) have shown that incubation of these cells in the pres-
ence of agonists for times as short as 60 min induces measurable
receptor loss. The apparent inhibition of binding seen at low
concentrations of these agonists more likely represents a con-
centration-effect curve for this receptor loss phenomenon than
inhibition by the agonists of 125I-Pin binding to high-affinity
receptors still present on the cells. The Kd values (11 ± 1 LMM
for isoproterenol, 240 ± 12 MuM for epinephrine) calculated from
the lower-affinity IC50 values are much higher than the Kact val-
ues (15 nM for isoproterenol, 50 nM for epinephrine) for stim-
ulation of cyclic AMP accumulation in intact cells and are also
much higher than the Kd values (38 nM for isoproterenol, 210
nM for epinephrine) for inhibition of binding to receptors in
membrane preparations. These results are similar to those pre-
viously reported in studies of other cultured cells (1-3); it is this
inconsonance between Kd and Kact values that our studies seek
to explain.
Inhibition of "2I-Pin binding to cells by isoproterenol and
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FIG. 3. Agonist competition binding curves with intact 1321N1 cells.
Intact 1321N1 cells were incubated with 125I-Pin and the indicated con-
centrations of (-)-isoproterenol (A) or (-)-epinephrine (B) at 37TC for
either 15 sec (e) or 60 min (a). The concentration of 125I-Pin used was
25 pM in the 60-min assays and between 50 and 150 pM in different
experiments involving 15-sec assays. Each data point is the mean ±
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FIG. 4. Competition binding curves for isoproterenol with intact
C62B cells. C62B cells were incubated with '25I-Pin and the indicated
concentrations of (-)-isoproterenol at 370C for either 15 sec (e) or 20
min (o). The concentration of "ssI-Pin used in different experiments was
between 25 and 100 pM for 15-sec assays and between 10 and 25 pM for
20-min assays. The results are the mean ± SEM from three experi-
ments.
When 15-sec assays were performed (Fig. 3), these agonists
were much more potent as inhibitors of 'NI-Pin binding than
was observed after a 60-min equilibrium binding-assay. These
data also were better fit by a two-component model. For iso-
proterenol, 81 ± 1% (n = 5) of 125I-Pin binding was inhibited
with an IC50 of 81 ± 4 nM and the remaining 19% was inhibited
with an ICso of 660 ± 130 ,uM. For epinephrine, 85 ± 4% (n
= 2) of "2I-Pin binding was inhibited with an IC50 of 470 +
5 nM and 15% was inhibited with an IC50 of 7,600 ± 760 ,uM.
Competition binding assays with isoproterenol also were
performed with C62B rat glioma cells. The curve obtained in
equilibrium assays (20 min, Fig. 4) was consistent with law of
mass action interaction of isoproterenol with a single class of
sites (Kd = 9.3 + 0.7 uM, n = 3), in good agreement with pre-
vious results (1, 11). This value is much higher than the Kact for
isoproterenol-stimulated cyclic AMP accumulation in these cells
[10 nM (1)] and than the Kd for inhibition by isoproterenol of
binding to receptors in membrane preparations [10-60 nM
(1)]. The curve obtained in 15-sec assays (Fig. 4) was better fit
by a two-component model, with 64 ± 2% (n = 3) of '251-Pin
binding inhibited with an IC50 of 85 ± 12 nM, and 36% in-
hibited with an IC50 of 850 ± 34 ,uM. The results obtained in
15-sec assays clearly indicate that in both 1321N1 and C62B
cells there is a high-affinity interaction of agonists with ,-ad-
renergic receptors that is not detected in longer time equilib-
rium binding assays at 37°C.
Isoproterenol competition for 125I-Pin binding to intact 1321N1
cells also was measured in equilibrium (6-hr) assays on ice with
100 pM 125I-Pin (data not shown). The data were better fit by
a two-component model with 86 ± 2% (n =- 3) of 125I-Pin bind-
ing inhibited with an ICso of 270 ± 35 nM (Kd = 53 + 6 nM)
and the remaining 14% inhibited with an IC50 of 68 ± 28 ,uM.
DISCUSSION
A valid measure of the equilibrium dissociation constant for a
competing ligand can be obtained under nonequilibrium con-
ditions of radioligand binding if two criteria are satisfied: (i) the
assay must approximate initial velocity conditions for radioli-
gand binding, and (ii) the competing ligand must be at equi-
librium with the receptor essentially throughout the time of
radioligand binding (see Theoretical Considerations). The high
affinity of 125I-Pin for intact cell f-adrenergic receptors and the
low level of nonspecific binding obtained even at short assay
times have allowed competition binding assays to be carried out
under conditions in which the radioligand-receptor interaction
is approximately at the initial velocity; thus the amount of bind-
ing obtained in the absence of competitor in the short-time as-
says was about 10% of that obtained in equilibrium assays. With
regard to the second criterion, previous studies suggest the rapid
attainment of equilibrium binding of isoproterenol to f3-adren-
ergic receptors on intact cells (19, 20). Rapid equilibration also
might be expected for epinephrine and metoprolol, because their
Kd values are similar to that for isoproterenol. The most im-
portant point with regard to these criteria, however, is that vi-
olation of either the initial velocity of radioligand binding as-
sumption or the rapid equilibration of competitor assumption
can lead only to an overestimate of the true value of the Kd for
the competitor; thus the affinity of intact cell A-adrenergic re-
ceptors for these ligands must be at least as high as indicated
by the short-time assays reported here. For the antagonist me-
toprolol (Fig. 1), the good agreement between the IC50 value
obtained in short-time assays and the Kd value calculated from
equilibrium binding assays suggests that both assumptions were
valid. This was not the case for the antagonist propranolol (Fig.
2), which exhibits a t1/2 to equilibrium of approximately 2 min
at concentrations near its Kd (data not shown); the slow equili-
bration of propranolol resulted in IC50 values from short-time
assays that were much larger than the true Kd.
Results obtained in short-time binding assays with isopro-
terenol and epinephrine in 1321N1 cells and with isoproterenol
in C62B cells suggest that agonists interact with two distinct
types of "2I-Pin binding sites having markedly different ago-
nist affinities. In all three cases the majority of the sites were
of high affinity, with Kd values only 5- to 10-fold higher than
their corresponding Kact values for stimulation of cyclic AMP
accumulation (summarized in Table 1). It is most likely through
interaction with these higher affinity sites that agonists act to
stimulate cyclic AMP accumulation. These higher-affinity Kd
values are also in good agreement with the Kd values deter-
mined in assays with membrane preparations. The nature and
significance of the 125I-Pin binding sites exhibiting the lower
affinity for agonists in short-time assays remains to be deter-
mined.
The results obtained in equilibrium assays with these ago-
nists in 1321N1 cells also appeared to indicate interaction with
two types of 125I-Pin binding sites of very different affinity.
However, the apparent high-affinity interaction observed at
low agonist concentrations most likely reflects agonist-induced
loss of "2I-Pin binding sites during the assay (7, 18). Thus after
a 60-min incubation in the presence of agonists, only low-af-
finity interaction of agonists is observed. A single low-affinity
interaction also was observed in equilibrium assays with C62B
cells. The Kd values obtained in these equilibrium assays are
100- to 500-fold higher than those observed in the short-time
assays and 500- to 5,000-fold higher than their corresponding
Kact values for stimulation of cyclic AMP accumulation (Table
1).
Previous work (1) had suggested that the low agonist affinity
observed in equilibrium assays with C62B cells was due to the
existence of "spare receptors" and not due to agonist-induced
Table 1. Summary of Kd and Kact values
Kd, nM Kact for
Equi- 15-sec Mem- intact cells,
Cells Ligand librium assay branes nM
1321N1 Isoproterenol 11,000 81 38 15
Epinephrine 240,000 470 210 50
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formation of a form of the receptor with low affinity for agonists
as described for L6 cells (2). From experiments in which intact
1321N1 or C62B cells were incubated with agonists before short-
time competition binding assays were performed, we have ob-
tained evidence for a rapid and reversible agonist-induced con-
version of intact cell f3-adrenergic receptors from the high-af-
finity form detected in short-time assays to a form of lower affinity
(unpublished data). This phenomenon most likely is reponsible
for most of the discrepancy observed between Kact values and
equilibrium Kd values. The remaining discrepancy may be due
to the coupling relationships between the f3-adrenergic recep-
tor, the guanine-nucleotide binding protein, and the enzyme
adenylate cyclase. Ratios of Kd/Kact that are somewhat greater
than 1.0 are not unexpected for coupled systems involving sev-
eral components (21-23).
A high-affinity interaction between isoproterenol and intact
1321N1 cell 03-adrenergic receptors also was observed in equi-
librium competition binding assays on ice. Insel and Sanda (24)
reported similar results in studies of S49 mouse lymphoma cells,
with agonists exhibiting higher binding affinity at 40C than at
370C. These results may indicate that binding interactions be-
tween receptor and ligands, both agonists and antagonists, can
occur normally on ice, but that a subsequent reaction that re-
sults in formation of a low-affinity form of the receptor at 370C
is blocked at low temperatures.
The results presented here confirm and extend those of Pitt-
man and Molinoff (2) and demonstrate that in a variety of cell
lines the 13-adrenergic receptor initially exhibits high-affinity ago-
nist binding, but that agonist binding subsequently converts
these receptors to a form exhibiting much lower agonist affin-
ity. Further studies of agonist-induced changes in the prop-
erties of intact cell A-adrenergic receptors (unpublished) sug-
gest that agonists promote internalization of cell surface recep-
tors. The relationship of the agonist-induced change in agonist
binding affinity observed with intact cells to receptor inter-
nalization and to the various aspects of catecholamine-induced
desensitization of the f3-adrenergic receptor-linked adenylate
cyclase system that have been described previously (5, 7-9) re-
main to be investigated.
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